Subject: BICX Bounce Play? Up 35% Today on Strong Volume

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BICX Bounce Play? Up 35% Today on Strong Volume
Hot Stock to WatchHot Stock to Watch

Company: BioCorRx Inc. (OTCQB: BICX)


Price: 0.0475

Change (%): + 0.0125 (35.71)

Volume: 212,326
BICX Chart

SeeThruEquity Initiates Coverage on BioCorRx Inc. with a Price Target of $0.13

NEW YORK, NY / ACCESSWIRE / July 22, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of BioCorRx Inc. (OTCQB: BICX) with a Price Target of $0.13.

The report is available here: BICX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

With headquarters in Santa Ana, CA, BICX distributes and licenses the Start Fresh Program for alcoholism and opioid addiction to a growing network of clinics and addiction treatment centers across the country. BICX has begun to experience accelerating business trends of late, with the number of treatment centers that offer the Start Fresh Program(R) more than doubling over the last six quarters, which has also been a catalyst for rapid revenue growth. Indeed, since a rebranding of the company and a focus on growing by finding licensing and distribution partners, BICX has seen its top line rising quickly. Revenues grew by 111% YoY in 1Q15 after growing more than 60% from 2013 to 2014. We expect the company to continue these trends in 2015E, and view BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.

“Given the multi-billion dollar market opportunity and even larger economic cost of treating alcohol and opioid substance abuse, as well as the lack of effective treatments in the current medical paradigm, we see a large opportunity for BICX as the company expands. With limited resources deployed to date, the company has more than doubled the number of clinics offering the Start Fresh Program in the last year while the number of patients undergoing the Start Fresh Program(R) treatment plan has risen by 402%. Considering the opportunity and apparent early traction garnered by the company, we see BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $0.13 per share.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks